Search Results

You are looking at 1 - 1 of 1 items for

  • Author or Editor: Natalia Ramos x
  • Refine by Content Type: All x
Clear All Modify Search
Maria Jose Soler and Natalia Ramos

During the last decade, several therapeutics targeting the complement cascade have begun to enter the nephrology scene (Figure 1). Examples include the following diseases:

Atypical hemolytic uremic syndrome (aHUS)

C3 glomerulopathy

Lupus nephritis

Anti-neutrophil cytoplasmic antibody (ANCA) vasculitis

Immunoglobulin A (IgA) nephropathy

Summary of the drugs that target the complement cascade in glomerular disease

IgAN, IgA nephropathy; C3GN, C3 glomerulonephritis; HUS, hemolytic uremic syndrome; SLE, systemic lupus erythematosus; AAV, anti-neutrophil cytoplasmic autoantibodies; MBL, mannose-binding lectin; MASP, mannose-binding lectin-associated serine protease; CR1, complement receptor type 1; CR2, complement receptor type 2; DAF, decay-accelerating factor; ALP2, alkaline protease